LUXEMBOURG – In a significant move to fortify Lebanon’s crumbling public health infrastructure, the World Health Organization (WHO) and the European Investment Bank (EIB Global) have announced a landmark €10 million grant agreement. The deal, signed on 6 March 2025 at the EIB Group Forum in Luxembourg, marks a pivotal intervention intended to stabilize a healthcare system that has been pushed to the brink by years of political instability, economic collapse, and regional volatility.
Dr. Tedros Adhanom Ghebreyesus, Director-General of the WHO, and Thomas Östros, Vice-President of the European Investment Bank, solidified the partnership, which aims to address two critical pillars of the Lebanese health sector: the restoration of diagnostic capabilities and the continuity of care for patients with life-threatening chronic conditions.
Main Facts: A Targeted Intervention
The €10 million financial injection is not a broad-spectrum aid package; rather, it is a surgical intervention designed to restore the backbone of Lebanon’s national public health system.
The initiative focuses on two primary outcomes:
- Re-establishment of the Central Public Health Laboratory (CPHL): For years, the CPHL has suffered from a lack of funding, outdated equipment, and the brain drain of specialized laboratory technicians. The grant will facilitate the procurement of modern diagnostic technology and the training of personnel, effectively returning the facility to its role as the nation’s primary hub for disease surveillance and outbreak detection.
- Continuity of Essential Care: The partnership aims to provide direct medication and logistical support to at least 50,000 vulnerable individuals living with chronic non-communicable diseases (NCDs), including diabetes, cardiovascular conditions, and various forms of cancer. In a country where the cost of imported medication has skyrocketed beyond the reach of the average citizen, this support acts as a critical safety net.
Chronology: The Road to the Luxembourg Agreement
The agreement signed in Luxembourg is the culmination of nearly two years of negotiations between international donors and the Lebanese Ministry of Public Health.
- 2022-2023: The Crisis Deepens: As the Lebanese pound lost over 90% of its value, the public health sector experienced a catastrophic exodus of doctors and nurses. Pharmacies reported persistent shortages of insulin, blood pressure medications, and oncology treatments.
- Late 2024: Strategic Assessment: WHO and EIB representatives conducted a series of on-the-ground assessments in Beirut. The findings were stark: the Central Public Health Laboratory was operating at a fraction of its capacity, and the mortality rate for patients with manageable chronic diseases was rising due to the inability to access basic medication.
- Early 2025: Drafting the Framework: Technical teams from both organizations drafted a memorandum of understanding, focusing on transparency, supply chain integrity, and the long-term sustainability of the laboratory facilities.
- 6 March 2025: Formalization: During the EIB Group Forum in Luxembourg, Dr. Tedros and Vice-President Östros officially signed the grant agreement, signaling the transition from planning to active implementation.
Supporting Data: Why Lebanon Needs This Support
To understand the necessity of this €10 million grant, one must examine the macro-economic and health indicators currently plaguing Lebanon.
The Erosion of Public Healthcare
According to recent WHO data, public sector healthcare expenditure in Lebanon has been severely curtailed by the national economic crisis. The Central Public Health Laboratory, which is meant to be the sentinel for epidemiological monitoring, has struggled to perform basic tests for infectious diseases.
The NCD Burden
Non-communicable diseases are the leading cause of mortality in Lebanon. Data from the Lebanese Ministry of Public Health indicates that:
- Cardiovascular disease accounts for nearly 40% of all deaths in the country.
- Diabetes prevalence is among the highest in the Middle East region, with approximately 15% of the adult population requiring consistent, high-quality insulin and monitoring.
- Oncology Treatment: The cost of a single chemotherapy cycle now represents more than several months’ worth of an average public-sector salary, making the 50,000-person support target vital for preventing a humanitarian tragedy.
Official Responses and Strategic Vision
The WHO Perspective
Dr. Tedros Adhanom Ghebreyesus emphasized that this partnership is about more than just equipment—it is about restoring trust. "The strength of a nation’s health system is defined by its ability to protect its most vulnerable during times of crisis," Dr. Tedros stated during the signing ceremony. "By restoring the Central Public Health Laboratory, we are ensuring that Lebanon has the eyes and ears it needs to detect future health threats, while providing the medicine that keeps the current population alive."
The EIB Global Perspective
Thomas Östros, representing the European Investment Bank, highlighted the strategic importance of investing in the Mediterranean region’s stability. "EIB Global is committed to supporting sustainable development. A healthy population is the foundation of economic recovery. This grant is a demonstration of Europe’s solidarity with the people of Lebanon. We are not just providing funds; we are building the infrastructure for a resilient future."
Implications: Building for the Future
Regional Health Security
The restoration of the Central Public Health Laboratory has implications that extend far beyond Lebanon’s borders. In an interconnected region, the ability of a country to conduct rapid, accurate diagnostic testing is a global public good. By strengthening Lebanon’s laboratory capacity, the WHO is effectively closing a diagnostic gap that could have served as a blind spot for regional disease outbreaks.
Addressing the Medication Crisis
The focus on 50,000 patients with chronic diseases is a strategic choice. By targeting NCDs, the WHO and EIB are attempting to prevent the "secondary mortality" caused by economic collapse. When patients stop taking blood pressure medication or miss insulin doses, the result is a massive influx of patients into already overwhelmed hospital emergency rooms. By providing the medication at the primary care level, this initiative will indirectly relieve pressure on the nation’s hospital system.
Challenges Ahead: Sustainability and Governance
Despite the optimism surrounding the announcement, experts warn that the initiative faces significant hurdles. The primary challenge is the volatility of the Lebanese socio-political environment. For the project to succeed, the EIB and WHO have implemented strict oversight mechanisms to ensure that medications reach their intended recipients rather than entering the black market, a common issue in conflict-affected regions.
Furthermore, the "re-establishment" of the CPHL is not merely a hardware problem. It requires the retention of skilled laboratory scientists. The project includes provisions for specialized training and incentive structures to ensure that the staff operating the new equipment remain in the country, effectively slowing the "brain drain" that has plagued the medical sector.
A Model for Future Partnerships
This grant could serve as a blueprint for future collaborations between development banks and international health agencies. By combining the financial muscle of the EIB with the technical expertise and diplomatic reach of the WHO, the international community can create more effective interventions in "fragile states."
If successful, this partnership could be expanded to include other aspects of the Lebanese health system, such as digital health infrastructure and maternal health services, providing a roadmap for how international institutions can assist countries in navigating the "poly-crisis" of the 21st century.
Conclusion
The signing in Luxembourg is a beacon of hope for a nation currently navigating its darkest chapter in modern history. While €10 million will not solve the entirety of Lebanon’s systemic health issues, it provides a crucial bridge. It addresses the immediate, life-saving needs of 50,000 people and reinforces the vital surveillance mechanisms that keep the entire population safe.
As the project moves into the implementation phase, the eyes of the international health community will be on Beirut. The success of this collaboration will serve as a testament to whether international aid can be effectively channeled to rebuild institutions from the ground up, even in the most challenging of circumstances. The partnership between the WHO and EIB Global is a definitive statement: even in times of extreme adversity, the right to health remains a non-negotiable priority.
About the Author
